← Leaderboards
De-Chu Christopher Tang
Vaxin Inc.
$4,264,366
Attributed
$4,264,366
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2005–10$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,264,366 · 6
By mechanism
UC1$2,435,173 · 1
R44$952,146 · 1
R42$565,250 · 1
R43$311,797 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentLaboratory MouseActive ImmunizationDoseDisease OutbreaksAdenovirusesCountryAntigensAdenovirus VectorCostAnimalsBacterial VaccinesBaseBiomedical EngineeringAntibodiesCodon NucleotidesBird DiseasesBird Flu VaccineBirdsBuffersChickensAdenoviridaeBackCommercialization
Grant awards (9)
In-ovo vaccination/avian influenza/bird/human$342,163
R44 · FY2010 · AI · contact PI
In-ovo vaccination/avian influenza/bird/human$277,604
R44 · FY2009 · AI · contact PI
In-ovo vaccination/avian influenza/bird/human$332,379
R44 · FY2008 · AI · contact PI
In-ovo vaccination/avian influenza/bird/human$111,797
R43 · FY2006 · AI · contact PI
Adenovirus-vectored nasal anthrax vaccine$2,435,173
UC1 · FY2005 · AI
Non-invasive delivery of skin-targeted tetanus vaccines$282,625
R42 · FY2002 · AI
Non-invasive delivery of skin-targeted tetanus vaccines$282,625
R42 · FY2001 · AI
Noninvasive delivery of skin-targeted anthrax vaccines$100,000
R43 · FY2001 · AI
NONINVASIVE DELIVERY OF SKIN-TARGETED RABIES VACCINES$100,000
R43 · FY2001 · AI